Compare Heron Therapeutics Inc (HRTX) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Annaly Capital Management, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.41 (market cap $68.01M), while Annaly Capital Management, Inc. trades at $18.3 (market cap $13.77B). The key difference: Annaly Capital Management, Inc. is far larger — about 202.5× Heron Therapeutics Inc's market cap, and Annaly Capital Management, Inc. pays a 16.42% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Annaly Capital Management, Inc. for 91 Days on average.
| HRTX | NLY | |
|---|---|---|
Market Cap | $68.01M | $13.77B |
Volume | 1,891,941 | 21,283,879 |
Sector | Health | Real Estate |
52-Week High | $1.49 | $24.40 |
52-Week Low | $0.27 | $17.93 |
Typical Hold Time | 35 Days | 91 Days |
Enterprise Value | $174.75M | $135.80B |
Dividend Yield | — | 16.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.4061, up 4.13% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed EPS estimates with a $0.03 loss. Despite negative profitability metrics (-22.52% net margin), analyst consensus remains strongly positive with 89% buy ratings. Recent news highlights ongoing comparisons with peers and earnings call discussions.
HRTX faces significant fundamental challenges with consistent losses and negative ROE, though revenue stability provides some foundation. The strong analyst support suggests potential upside if operational improvements materialize, but high execution risk and cash flow concerns warrant caution for investors seeking near-term profitability.
NLY trades at $18.30, up 2.06% today, with a bearish technical signal from moving averages but oversold RSI readings. The stock shows strong profitability with a 92.77% net income margin and a low P/E of 4.41. Recent earnings have consistently beaten estimates, and the company maintains a high dividend yield near 15%, supported by a $0.75 quarterly payout announced for Q3 2026.
The outlook is mixed: attractive valuation and high yield offer upside potential, but significant cash flow volatility and rising debt-to-asset ratio pose risks. Analyst consensus is bullish with a $22.00 price target, yet technical weakness and interest rate sensitivity warrant caution for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
